Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C. 30855203

2019

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection. 29872876

2018

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE Ribavirin, a nucleic acid analog, has been employed as an antiviral agent against RNA and DNA viruses and has become the standard agent used for chronic hepatitis C in combination with interferon-α2a. 29251333

2018

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE The gene targets were selected in patients with the IFN-mediated disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and an adult patient with chronic hepatitis C who received the first dose of pegylated interferon alpha-2a. 29638206

2018

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE A total of 447 chronic hepatitis C (CHC) patients (including 328 treated with interferon alpha-2b and ribavirin), 129 individuals who had spontaneously cleared HCV (SHC), and 169 healthy controls were retrospectively investigated. ss469415590 genotyping was performed using a mass spectrometry method (SEQUENOM). 26820907

2016

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. 27492396

2016

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE The aim of this study was to assess the impact of nitazoxanide as an add-on therapy to pegylated interferon α-2a and ribavirin on sustained virologic response (SVR) in patients with chronic hepatitis C. 26473300

2016

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. 25298576

2015

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. 24730368

2014

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. 24782620

2014

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. 24278242

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. 23406826

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE A total of 145 adult patients diagnosed with genotype 1 chronic hepatitis C (CHC) who had completed a 48-wk regimen of pegylated-interferon α-2a or -2b plus ribavirin combination therapy were recruited from six large urban healthcare centers and 199 healthy blood donors (controls) from a single site between January 2010 and January 2012. 24259970

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial. 23396736

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1. 23524524

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis. 23436591

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. 23942001

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. 23439365

2013

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1. 22799464

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). 22267474

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE A 62-year-old male treated with pegylated interferon α-2b plus ribavirin for chronic hepatitis C complained of sudden painless decreased visual acuity. 22172047

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. 22098185

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. 22899224

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 GeneticVariation BEFREE Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. 22613000

2012

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.400 Biomarker BEFREE Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. 22300892

2012